Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-19
DOI
10.1002/cpt.1953
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1
- (2020) Yulia Vugmeyster et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
- (2019) Edwin A. Basak et al. EUROPEAN JOURNAL OF CANCER
- Exposure‐response analysis of overall survival for tremelimumab in unresectable malignant mesothelioma: the confounding effect of disease status
- (2019) Paul Baverel et al. CTS-Clinical and Translational Science
- Nivolumab Clearance Is Stationary in Resected Melanoma Patients on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance
- (2019) Lora Hamuro et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types
- (2019) Justin J. Wilkins et al. ADVANCES IN THERAPY
- Letter to the Editor: Exposure–response or clearance–response relationship in immune checkpoint therapy?—A comment on ‘correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer’ by Basak et al
- (2019) Mohamed Badawi et al. EUROPEAN JOURNAL OF CANCER
- A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
- (2019) Daan P. Hurkmans et al. Journal for ImmunoTherapy of Cancer
- Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
- (2019) Kari M. Morrissey et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
- (2019) René Bruno et al. CLINICAL CANCER RESEARCH
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
- (2018) Sirisha L. Mushti et al. CLINICAL CANCER RESEARCH
- Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
- (2018) David Turner et al. CLINICAL CANCER RESEARCH
- Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
- (2018) Cora N. Sternberg et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- (2018) Paul G. Baverel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
- (2018) Yan Ji et al. CTS-Clinical and Translational Science
- Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials
- (2018) Naveen Mangal et al. HEMATOLOGICAL ONCOLOGY
- Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.
- (2018) Yulia Vugmeyster et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials
- (2017) Naveen Mangal et al. HEMATOLOGICAL ONCOLOGY
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- (2017) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
- (2017) Gaurav Bajaj et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
- (2017) Hongshan Li et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
- (2017) Josep Tabernero et al. MOLECULAR CANCER THERAPEUTICS
- Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials
- (2017) Suresh K. Agarwal et al. Journal of Cancer
- Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer
- (2016) Kelong Han et al. AAPS Journal
- Understanding cachexia as a cancer metabolism syndrome
- (2016) P E Porporato Oncogenesis
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
- (2015) M Zhu et al. BRITISH JOURNAL OF CANCER
- Rilotumumab Exposure-Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
- (2015) S. Doshi et al. CLINICAL CANCER RESEARCH
- Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials
- (2014) R Bruno et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma
- (2014) Erjian Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib
- (2014) Yi Ling Teo et al. Targeted Oncology
- Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response
- (2013) Brendan C. Bender et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- (2013) Y. Feng et al. CLINICAL CANCER RESEARCH
- Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making
- (2012) Jun Yang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study
- (2011) James P Morden et al. BMC Medical Research Methodology
- The cachexia score (CASCO): a new tool for staging cachectic cancer patients
- (2011) Josep M. Argilés et al. Journal of Cachexia Sarcopenia and Muscle
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing
- (2008) Marina Kacevska et al. Expert Opinion on Drug Metabolism & Toxicology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now